are reinvested by the average pharma company into the sales force to push the future business
Which future sales and profits can you expect?
What is the optimization potential?
And how to achieve it?
offers a useful prediction. This burns money.
Some drivers cannot be controlled (market churn, competitor approvals), others only in the long-run (R&D pipeline)
Therefore, our solution optimizes the driver with biggest immediate impact: sales force size, allocation and channel mix
It focuses the sales force activities on regions, brands and channels with high customer response
It predicts the impact of this optimized sales force and channel deployment on future sales and profits
It is applicable for all life cycle stages – from product launch to late-stage commercialization
Interested in how it works?
Book a demo
Results from initial study with 1.7 bn UK data
1. Higher customer response
2. +5-10% profit upside
3. 60-90% less planning work
